Update, Phase 2 trial results: FC705 Outperforms Pluvicto
FC705, a new radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC), outperformed Pluvicto in phase 2 trials, achieving a 60.0% tumor response rate compared to Pluvicto’s 29.8% (and it works on both lymphnode and bone metastases, Pluvicto works only on lymphnode mets).
FC705, a new radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC), outperformed Pluvicto in phase 2 trials, achieving a 60.0% tumor response rate compared to Pluvicto’s 29.8% (and it works on both lymphnode and bone metastases, Pluvicto works only on lymphnode mets).